Tenforde Mark W, Milton Thandi, Rulaganyang Ikanyeng, Muthoga Charles, Tawe Leabaneng, Chiller Tom, Greene Gregory, Jordan Alexander, Williams Christopher G, Owen Leah, Leeme Tshepo B, Boose Amber, Ngidi Julia, Mine Madisa, Jarvis Joseph N
Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington, USA.
Clin Infect Dis. 2021 May 4;72(9):1635-1638. doi: 10.1093/cid/ciaa899.
Increasing the CD4-count threshold for cryptococcal antigen (CrAg) screening from ≤100 to ≤200 cells/µL resulted in a 3-fold increase in numbers screened. CrAg-prevalence was 3.5% at CD4 101-200 and 6.2% ≤100 cells/µL. Six-month mortality was 21.4% (9/42) in CrAg-positive CD4 ≤100 cells/µL and 3.2% (1/31) in CrAg-positive CD4 101-200 cells/µL.
将隐球菌抗原（CrAg）筛查的CD4细胞计数阈值从≤100个细胞/µL提高到≤200个细胞/µL，导致筛查人数增加了两倍。CD4为101 - 200时CrAg患病率为3.5%，CD4≤100个细胞/µL时为6.2%。CD4≤100个细胞/µL的CrAg阳性患者6个月死亡率为21.4%（9/42），CD4为101 - 200个细胞/µL的CrAg阳性患者为3.2%（1/31）。
